Colchicine in combination with infliximb compared with infliximb in the treatment of patients with Covidian 19

Phase 2

Conditions: COVID-19.
COVID-19, virus identified
U07.1

Registration Number: IRCT20200325046854N2

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 70

Inclusion Criteria

Patients with the common type of Novel Coronavirus Pneumonia (NCP) (at high risk) and other severe cases of newly diagnosed coronavirus pneumonia between the ages of 18 and 85 with an increase in IL-6 levels if the patient or his or her judge agrees to participate. Study and after signing the informed consent entered the study. Definition of clinical cases of the novel Coronavirus Pneumonia (NCP) :. 1. Specifications with NCP (with serious risk factors): Contains lung lesions based on common clinical signs of NCP with or without fever. 2. NCP critical patient.

Exclusion Criteria

1. Patients participating in other clinical studies 2. Pregnant or lactating women; 3. Patients receiving immunomodulatory drugs to prevent graft rejection or other cases; 4. Allergy to any of the drug compounds; 5. Patients with active pulmonary tuberculosis, with specific bacterial and fungal infections; Patients with malignancy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of clinical symptoms. Timepoint: Before the intervention and daily during the intervention. Method of measurement: Clinical evaluation of the patient/ Questionnaire.;Evaluation of pulmonary CT scan changes. Timepoint: Before the intervention and every other day during the intervention. Method of measurement: Pulmonary CT scan.

Secondary Outcome Measures